<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/24/analysts-expect-immunomedics-inc-nasdaqimmu-will-post-earnings-of-0-45-per-share.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-24T19:12:41+00:00"/>
    <meta property="og:title" content="Analysts Expect Immunomedics, Inc. (NASDAQ:IMMU) Will Post Earnings of -$0.45 Per Share"/>
    <meta property="og:description" content="Analysts expect Immunomedics, Inc. (NASDAQ:IMMU) to report earnings of ($0.45) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Immunomedics’ earnings. The highest EPS estimate is ($0.39) and the lowest is ($0.52). Immunomedics posted earnings per share of ($0.50) in the same quarter last year, which indicates […]"/>
  </head>
  <body>
    <article>
      <h1>Analysts Expect Immunomedics, Inc. (NASDAQ:IMMU) Will Post Earnings of -$0.45 Per Share</h1>
      <address><time datetime="2019-11-24T19:12:41+00:00">24 Nov 2019, 19:12</time> by <a rel="author" href="https://www.thecerbatgem.com/author/renee" target="_blank">Renee Jackson</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/immunomedics-incorporated-logo.jpg"/>
      </figure>
      <p>Analysts expect Immunomedics, Inc. (NASDAQ:IMMU) to report earnings of ($0.45) per share for the current fiscal quarter, <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> reports. Zero analysts have issued estimates for Immunomedics’ earnings. The highest EPS estimate is ($0.39) and the lowest is ($0.52). Immunomedics posted earnings per share of ($0.50) in the same quarter last year, which indicates a positive year-over-year growth rate of 10%. The firm is scheduled to report its next earnings results on Monday, February 24th.</p>
      <p>According to Zacks, analysts expect that Immunomedics will report full-year earnings of ($1.78) per share for the current fiscal year, with EPS estimates ranging from ($1.87) to ($1.60). For the next fiscal year, analysts anticipate that the firm will post earnings of ($1.59) per share, with EPS estimates ranging from ($1.82) to ($1.32). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that cover Immunomedics.</p>
      <p>Immunomedics (NASDAQ:IMMU) last released its quarterly earnings data on Wednesday, October 30th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.09). During the same quarter last year, the business earned ($0.34) earnings per share.</p>
      <p>A number of equities analysts have recently issued reports on IMMU shares. Piper Jaffray Companies raised their price objective on Immunomedics from $20.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 6th. B. Riley set a $28.00 price objective on Immunomedics and gave the stock a “buy” rating in a research report on Monday, September 30th. HC Wainwright restated a “buy” rating and set a $26.00 price objective on shares of Immunomedics in a research report on Thursday, October 31st. Cantor Fitzgerald began coverage on Immunomedics in a research report on Monday, August 19th. They set an “overweight” rating and a $28.00 price objective for the company. Finally, Wells Fargo &amp; Co lifted their target price on Immunomedics from $14.00 to $16.00 and gave the stock a “market perform” rating in a report on Monday, September 30th. Two investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $26.22.</p>
      <p><a href="https://www.marketbeat.com/stocks/NASDAQ/IMMU/earnings/">NASDAQ:IMMU</a> traded up $0.16 during trading hours on Friday, hitting $18.56. The company’s stock had a trading volume of 995,300 shares, compared to its average volume of 1,745,337. Immunomedics has a twelve month low of $11.55 and a twelve month high of $21.23. The company has a debt-to-equity ratio of 0.30, a current ratio of 6.51 and a quick ratio of 6.51. The company has a market capitalization of $3.56 billion, a P/E ratio of -18.02 and a beta of 2.13. The stock has a fifty day simple moving average of $16.21 and a 200-day simple moving average of $14.79.</p>
      <p>In other Immunomedics news, Director Avoro Capital Advisors Llc bought 1,000,000 shares of the stock in a transaction on Wednesday, October 2nd. The stock was acquired at an average cost of $13.23 per share, for a total transaction of $13,230,000.00. The acquisition was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through <a href="https://www.sec.gov/Archives/edgar/data/722830/000090266419003903/xslF345X03/ownership.xml">this link</a>. Also, insider Bryan Ball bought 5,000 shares of the stock in a transaction on Thursday, October 3rd. The stock was acquired at an average price of $14.18 per share, with a total value of $70,900.00. Following the completion of the acquisition, the insider now owns 10,000 shares of the company’s stock, valued at approximately $141,800. The disclosure for this purchase can be found <a href="https://www.sec.gov/Archives/edgar/data/722830/000110465919053001/xslF345X03/a4.xml">here</a>. Insiders own 9.40% of the company’s stock.</p>
      <p>Several hedge funds and other institutional investors have recently added to or reduced their stakes in IMMU. Boxer Capital LLC increased its holdings in shares of Immunomedics by 60.2% during the second quarter. Boxer Capital LLC now owns 6,567,000 shares of the biopharmaceutical company’s stock valued at $91,084,000 after acquiring an additional 2,467,000 shares in the last quarter. BlackRock Inc. increased its holdings in shares of Immunomedics by 9.9% during the second quarter. BlackRock Inc. now owns 13,798,803 shares of the biopharmaceutical company’s stock valued at $191,389,000 after acquiring an additional 1,239,462 shares in the last quarter. Menora Mivtachim Holdings LTD. increased its holdings in shares of Immunomedics by 181.4% during the third quarter. Menora Mivtachim Holdings LTD. now owns 1,434,900 shares of the biopharmaceutical company’s stock valued at $19,027,000 after acquiring an additional 925,000 shares in the last quarter. Peregrine Capital Management LLC bought a new stake in shares of Immunomedics during the third quarter valued at approximately $11,412,000. Finally, Nuveen Asset Management LLC bought a new stake in shares of Immunomedics during the second quarter valued at approximately $9,294,000. Hedge funds and other institutional investors own 88.49% of the company’s stock.</p>
      <p>
        <b>About Immunomedics</b>
      </p>
      <p>Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively.</p>
      <p>Featured Article: <a href="https://www.marketbeat.com/financial-terms/what-member-countries-make-up-the-g-20/">What is the role of the G-20?</a></p>
      <p>
        <a href="https://www.zacks.com/registration/pfp/?ALERT=ZER_LINK&amp;ADID=AMERBMN_CONTENT_ZER&amp;skip_rpt_name_check=skip_rpt_name_check&amp;t=IMMU">Get a free copy of the Zacks research report on Immunomedics (IMMU)</a>
      </p>
      <p>For more information about research offerings from Zacks Investment Research, visit <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks.com</a></p>
      <figure>
        <img src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=IMMU"/>
      </figure>
    </article>
  </body>
</html>